Standard BioTools to merge with Treeline Biosciences in all-stock transaction
Standard BioTools Inc. entered into a definitive merger agreement with Treeline Biosciences, Inc. on June 6, 2026, whereby Treeline will merge with Standard BioTools' subsidiary, with the combined company operating as Treeline Biosciences Holdings, Inc. The all-stock transaction values Treeline at $2.5 billion and Standard BioTools at $460 million (adjusted for net cash), with Standard BioTools stockholders expected to own approximately 16% and Treeline stockholders approximately 84% of the combined company on a fully diluted basis at closing, expected in the second half of 2026. Standard BioTools must pursue strategic options to divest or monetize its mass cytometry and microfluidics businesses, with proceeds flowing to pre-merger Standard BioTools stockholders through contingent value rights.
Key facts
- Merger Agreement dated June 6, 2026 among Standard BioTools Inc., Treeline Biosciences, Inc., and Siri Merger Sub, Inc.
- Treeline equity value of $2.5 billion; Standard BioTools equity value of $460 million, reduced by net cash shortfall or increased by net cash surplus relative to $449 million–$451 million range
- Pre-merger Standard BioTools stockholders expected to hold approximately 16% of combined company on fully diluted basis; pre-merger Treeline stockholders approximately 84%
- Company stockholders comprising required majorities delivered written consent adopting Merger Agreement on June 6, 2026
- Standard BioTools stockholders to receive one contingent value right per share, representing right to receive payments based on proceeds from legacy assets and Illumina earnout payments
- Exchange Ratio calculated based on relative capitalization of each party and parent net cash adjustments
- Treeline Options and Treeline Converting Warrants to be assumed or converted into Standard BioTools Common Stock based on Exchange Ratio
- Termination fee of $16.1 million payable by Standard BioTools if merger terminates due to change in Standard BioTools Board recommendation
- Standard BioTools obligated to reimburse Treeline's reasonable out-of-pocket fees up to $5 million if Merger Agreement terminated due to failure to obtain Standard BioTools stockholder approval
- Combined company board to consist of 12 members: 10 designated by Treeline, 2 by Standard BioTools
- Dr. Josh Bilenker (Treeline CEO), Dr. Jeff Engelman (Treeline CSO), and Spencer Smith (Treeline CFO) to lead combined company
- Expected closing in second half of 2026, subject to Standard BioTools stockholder approval, Hart-Scott-Rodino clearance, and S-4 effectiveness
Why it matters
The transaction represents a significant consolidation in biopharma, combining Standard BioTools' cash and balance sheet with Treeline's clinical-stage drug pipeline, with the combined company expected to hold over $900 million in cash and operate as a biopharma company, while Standard BioTools' legacy businesses face uncertain futures through required divestiture.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-08. Not investment advice. View the source filing on SEC.gov →